AptaBio Therapeutics Past Earnings Performance
Past criteria checks 0/6
AptaBio Therapeutics's earnings have been declining at an average annual rate of -50.5%, while the Biotechs industry saw earnings growing at 1.6% annually. Revenues have been growing at an average rate of 5430.6% per year.
Key information
-50.5%
Earnings growth rate
-50.5%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 5,430.6% |
| Return on equity | -41.5% |
| Net Margin | -691.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
AptaBio Therapeutics (KOSDAQ:293780) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Oct 29
Is AptaBio Therapeutics (KOSDAQ:293780) Using Too Much Debt?
Jul 12Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money
Mar 26Do Institutions Own AptaBio Therapeutics Inc. (KOSDAQ:293780) Shares?
Feb 23Companies Like AptaBio Therapeutics (KOSDAQ:293780) Can Afford To Invest In Growth
Jan 01
Revenue & Expenses Breakdown
How AptaBio Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,906 | -20,102 | 5,542 | 13,933 |
| 30 Jun 24 | 2,055 | -16,245 | 352 | 17,198 |
| 31 Mar 24 | 942 | -11,012 | 2,693 | 14,019 |
| 31 Dec 23 | 324 | -11,867 | 3,915 | 12,380 |
| 30 Sep 23 | 53 | -13,357 | 3,626 | 9,240 |
| 31 Dec 22 | 48 | -10,565 | 2,788 | 6,197 |
Quality Earnings: A293780 is currently unprofitable.
Growing Profit Margin: A293780 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if A293780's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare A293780's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A293780 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-1.3%).
Return on Equity
High ROE: A293780 has a negative Return on Equity (-41.45%), as it is currently unprofitable.